After facing fierce competition at the Startup Awards Slovakia 2016, MultiplexDX placed first in the SCIENCE category, and took home the prestigious Overall Winner award. The jury was impressed by both MultiplexDX’s professional business approach as well as its revolutionary, proprietary technology aiming to eliminate cancer misdiagnosis with personalized, 100% accurate, life-saving tests.
The MultiplexDX team is confident this distinguished recognition will help the company get good traction and exponential growth in the global biotech diagnostics market.
Dr. Pavol Cekan, Founder and CEO of MultiplexDX, comments:
“We thank all who helped us achieve this victory: Our families, our investor— Neulogy Ventures— and all friends who remained by our side during the past year of our company’s existence.”
The founders of MultiplexDX, Drs. Pavol Cekan and Vladimir Wolf, possess both scientific and commercial experience, gained during their academic and professional careers in world-renowned cancer research and molecular diagnostics institutions such as the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, and Queens University (Canada).
During the first year, the company raised all necessary investments, launched two innovative biotech laboratories in the U.S. and Europe, significantly exceeded planned revenue growth, and was chosen as one of the TOP 100 innovative companies in Slovakia.
Video at the top of the page includes MDX’s presentation as well as the awards ceremony.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.